Survival in sensitized lung transplant recipients with perioperative desensitization

American Journal of Transplantation

Volumn 15, Issue 2, 2015, Pages 417-426

  Tinckam, K J ^a   Keshavjee, S ^a   Chaparro, C ^a   Barth, D ^a   Azad, S ^a   Binnie, M ^a   Chow, C W ^a   De Perrot, M ^a   Pierre, A F ^a   Waddell, T K ^a   Yasufuku, K ^a   Cypel, M ^a   Singer, L G ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

alloantibody; clinical research practice; desensitization; histocompatibility; lung disease; lung transplantation pulmonology; patient survival; rejection

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; DONOR SPECIFIC HLA ANTIBODY; HLA A ANTIGEN; HLA ANTIBODY; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN; MEPREDNISONE; MYCOPHENOLIC ACID; PANEL REACTIVE ANTIBODY; PREDNISONE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; LYMPHOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CONTROLLED STUDY; DESENSITIZATION; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GRAFT RECIPIENT; GRAFT SURVIVAL; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LUNG FUNCTION TEST; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; PLASMAPHERESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; AGED; CANADA; COHORT ANALYSIS; FOLLOW UP; LUNG; MIDDLE AGED; MORTALITY; PHYSIOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SURGERY; TREATMENT OUTCOME; VITAL CAPACITY;

ADULT; AGED; ANTILYMPHOCYTE SERUM; CANADA; COHORT STUDIES; DESENSITIZATION, IMMUNOLOGIC; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LUNG; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PERIOPERATIVE CARE; PLASMA EXCHANGE; RETROSPECTIVE STUDIES; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84921485115     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13076     Document Type: Article

References (36)

1. Organ procurement and transplantation network (OPTN) and scientific registry of transplant recipients (SRTR). OPTN/SRTR 2011 Annual Data Report. Rockville, MD, 2012.
2. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th Adult Lung and Heart-Lung Transplant Report-2012. J Heart Lung Transplant 2012; 31: 1073-1086.
3. Hadjiliadis D, Chaparro C, Reinsmoen NL, et al. Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study. J Heart Lung Transplant 2005; 24: S249-S254.
4. Shah AS, Nwakanma L, Simpkins C, Williams J, Chang DC, Conte JV., Pretransplant panel reactive antibodies in human lung transplantation: an analysis of over 10,000 patients. Ann Thorac Surg 2008; 85: 1919-1924.
5. Brugiere O, Suberbielle C, Thabut G, et al. Lung transplantation in patients with pretransplantation donor-specific antibodies detected by Luminex assay. Transplantation 2013; 95: 761-765.
6. Kim M, Townsend KR, Wood IG, et al. Impact of pretransplant anti-HLA antibodies on outcomes in lung transplant candidates. Am J Respir Crit Care Med 2014; 189: 1234-1239.
7. Smith JD, Ibrahim MW, Newell H, et al. Pre-transplant donor HLA-specific antibodies: Characteristics causing detrimental effects on survival after lung transplantation. J Heart Lung Transplant 2014; 33: 1074-1082.
8. Snyder LD, Wang Z, Chen DF, et al. Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients. Chest 2013; 144: 226-233.
9. Lobo LJ, Aris RM, Schmitz J, Neuringer IP., Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation. J Heart Lung Transplant 2013; 32: 70-77.
10. Witt CA, Gaut JP, Yusen RD, et al. Acute antibody-mediated rejection after lung transplantation. J Heart Lung Transplant 2013; 32: 1034-1040.
11. Hachem RR, Yusen RD, Meyers BF, et al. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant 2010; 29: 973-980.
12. Palmer SM, Davis RD, Hadjiliadis D, et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 2002; 74: 799-804.
13. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318-326.
14. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256-3262.
15. Snyder LD, Gray AL, Reynolds JM, et al. Antibody desensitization therapy in highly sensitized lung transplant candidates. J Heart Lung Transplant 2014; 14: 849-856.
16. Appel JZ 3rd, Hartwig MG, Davis RD, Reinsmoen NL., Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens. Hum Immunol 2005; 66: 378-386.
17. Tait BD, Susal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95: 19-47.
18. Reed EF, Rao P, Zhang Z, et al. Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. J Heart Lung Transplant 2013; 13: 1859-1870.
19. HRSA-OPTN. cPRA Calculator. Available at: http://optn.transplant.hrsa.gov/resources/allocationcalculators.asp?index=78. Accessed 2008-2012.
20. Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D., Report of the ISHLT Working Group on Primary Lung Graft Dysfunction Part II: Definition. A Consensus Statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2005; 24: 1454-1459.
21. Yousem SA, Berry G, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: lung rejection study group. J Heart Lung Transplant 1996; 15: 1-15.
22. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: An update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297-310.
23. Freitas MC, Rebellato LM, Ozawa M, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation 2013; 95: 1113-1119.
24. Zeevi A, Lunz J, Feingold B, et al. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant 2013; 32: 98-105.
25. Otten HG, Verhaar MC, Borst HP, Hene RJ, van Zuilen AD., Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 2012; 12: 1618-1623.
26. Palmer SM, Baz MA, Sanders L, et al. Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation 2001; 71: 1772-1776.
27. McNeil K, Glanville AR, Wahlers T, et al. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation 2006; 81: 998-1003.
28. Archdeacon P, Chan M, Neuland C, et al. Summary of FDA antibody-mediated rejection workshop. Am J Transplant 2011; 11: 896-906.
29. Amico P, Honger G, Bielmann D, et al. Incidence and prediction of early antibody-mediated rejection due to non-human leukocyte antigen-antibodies. Transplantation 2008; 85: 1557-1563.
30. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398-1406.
31. Susal C, Ovens J, Mahmoud K, et al. No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: A Collaborative Transplant Study report. Transplantation 2011; 91: 883-887.
32. Gloor JM, Winters JL, Cornell LD, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10: 582-589.
33. Patel AM, Pancoska C, Mulgaonkar S, Weng FL., Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 2007; 7: 2371-2377.
34. Bielmann D, Honger G, Lutz D, Mihatsch MJ, Steiger J, Schaub S., Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant 2007; 7: 626-632.
35. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369: 1215-1226.
36. Tikkanen JM, Singer L, Azad S, et al. De novo DQ donor-specific antibodies are associated with chronic lung allograft dysfunction. J Heart Lung Transplant 2014; 33: S98-S99.